More about
Secondary Progressive Multiple Sclerosis
News
April 04, 2025
1 min read
Save
Tolebrutinib slows disability accumulation in secondary progressive multiple sclerosis
SAN DIEGO — Treatment with tolebrutinib led to greater confirmed disability improvement at 6 months compared with placebo in patients with non-relapsing secondary progressive multiple sclerosis, according to research presented at AAN.
CME
Video
Expert Insights on COVID-19 Prophylaxis in Patients With Multiple Sclerosis and Related Disorders
This activity is supported by an independent educational grant from AstraZeneca Pharmaceuticals.
Clinical Guidance
Multiple Sclerosis
Assessment and Treatment
Assessment of Multiple Sclerosis
Clinical Guidance
Multiple Sclerosis
Assessment and Treatment
Treatment Options
Clinical Guidance
Multiple Sclerosis
Overview
Pathophysiology
Clinical Guidance
Multiple Sclerosis
Overview
Etiology and Risk Factors
Clinical Guidance
Multiple Sclerosis
Overview
Definition and Classification
CME
Video
Overcoming Obstacles to Optimal Multiple Sclerosis (MS) Care in Minority Patient Populations
Supported by an educational grant from Biogen.
CME
Ace the Case
Ace the Case: A 52-Year-Old Woman With Gradual Walking Difficulties
There is no commercial support for this activity.
CME
Ace the Case
Ace the Case: A 32-Year-Old Woman With Aphasia and Hemiparesis
There is no commercial support for this activity.